Hodges Capital Management Inc. decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 11.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 14,638 shares of the company’s stock after selling 1,875 shares during the quarter. Hodges Capital Management Inc.’s holdings in Eli Lilly and were worth $1,252,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. increased its stake in Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after purchasing an additional 59,978,664 shares during the period. Janus Henderson Group PLC increased its stake in Eli Lilly and by 7,093.5% in the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after purchasing an additional 9,223,251 shares during the period. Dodge & Cox grew its position in shares of Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after buying an additional 5,964,955 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after buying an additional 2,714,505 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the last quarter. Institutional investors and hedge funds own 76.42% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 641,088 shares of company stock valued at $54,480,286. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Company (LLY) traded up $1.18 during trading on Thursday, reaching $87.89. The company had a trading volume of 5,786,800 shares, compared to its average volume of 3,683,472. The stock has a market capitalization of $95,475.95, a PE ratio of 21.20, a PEG ratio of 1.77 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Company has a 12 month low of $67.54 and a 12 month high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 earnings per share. equities research analysts anticipate that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a $0.5625 dividend. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.56%. Eli Lilly and’s dividend payout ratio is presently 98.58%.

A number of equities research analysts have recently weighed in on LLY shares. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a research report on Thursday, September 28th. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a research report on Friday, October 13th. Jefferies Group restated a “buy” rating and set a $89.00 price target (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, Goldman Sachs Group restated a “buy” rating and set a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $90.25.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/hodges-capital-management-inc-cuts-stake-in-eli-lilly-and-company-lly/1763540.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with Analyst Ratings Network's FREE daily email newsletter.